170 related articles for article (PubMed ID: 37990076)
21.
Wong A; Callahan J; Keyaerts M; Neyns B; Mangana J; Aberle S; Herschtal A; Fullerton S; Milne D; Iravani A; McArthur GA; Hicks RJ
Cancer Imaging; 2020 May; 20(1):36. PubMed ID: 32408884
[TBL] [Abstract][Full Text] [Related]
22. TNM staging for GIT cancers is correlated with the level of MMPs and TGF-β1.
El-Ashmawy NE; Khedr NF; Mansour MG; Al-Ashmawy GM
Clin Exp Med; 2020 Nov; 20(4):545-555. PubMed ID: 32772210
[TBL] [Abstract][Full Text] [Related]
23. Immunotherapies in non-metastatic gastrointestinal cancers.
Saúde-Conde R; Nguyen D; Hendlisz A
Curr Opin Oncol; 2023 Jul; 35(4):334-346. PubMed ID: 37222204
[TBL] [Abstract][Full Text] [Related]
24. First-line nivolumab plus chemotherapy vs chemotherapy in patients with advanced gastric, gastroesophageal junction and esophageal adenocarcinoma: CheckMate 649 Chinese subgroup analysis.
Liu T; Bai Y; Lin X; Li W; Wang J; Zhang X; Pan H; Bai C; Bai L; Cheng Y; Zhang J; Zhong H; Ba Y; Hu W; Xu R; Guo W; Qin S; Yang N; Lu J; Shitara K; Lei M; Li M; Bao N; Chen T; Shen L
Int J Cancer; 2023 Feb; 152(4):749-760. PubMed ID: 36121651
[TBL] [Abstract][Full Text] [Related]
25. Neutrophil-to-Lymphocyte Ratio to Predict the Efficacy of Immune Checkpoint Inhibitor in Upper Gastrointestinal Cancer.
Booka E; Kikuchi H; Haneda R; Soneda W; Kawata S; Murakami T; Matsumoto T; Hiramatsu Y; Takeuchi H
Anticancer Res; 2022 Jun; 42(6):2977-2987. PubMed ID: 35641297
[TBL] [Abstract][Full Text] [Related]
26. Immunomodulatory Therapy Does Not Increase the Risk of Cancer in Persons With Inflammatory Bowel Disease and a History of Extracolonic Cancers.
Mañosa M; Chaparro M; Juan A; Aràjol C; Alfaro I; Mínguez M; Velayos B; Benítez JM; Mesonero F; Sicilia B; Zabana Y; Villoria A; Gisbert JP; Domènech E;
Am J Gastroenterol; 2019 May; 114(5):771-776. PubMed ID: 31082839
[TBL] [Abstract][Full Text] [Related]
27. Safety of Nivolumab plus Low-Dose Ipilimumab in Previously Treated Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer.
Morse MA; Overman MJ; Hartman L; Khoukaz T; Brutcher E; Lenz HJ; Atasoy A; Shangguan T; Zhao H; El-Rayes B
Oncologist; 2019 Nov; 24(11):1453-1461. PubMed ID: 31147488
[TBL] [Abstract][Full Text] [Related]
28. Niraparib plus nivolumab or niraparib plus ipilimumab in patients with platinum-sensitive advanced pancreatic cancer: a randomised, phase 1b/2 trial.
Reiss KA; Mick R; Teitelbaum U; O'Hara M; Schneider C; Massa R; Karasic T; Tondon R; Onyiah C; Gosselin MK; Donze A; Domchek SM; Vonderheide RH
Lancet Oncol; 2022 Aug; 23(8):1009-1020. PubMed ID: 35810751
[TBL] [Abstract][Full Text] [Related]
29. A global assessment of recent trends in gastrointestinal cancer and lifestyle-associated risk factors.
Lu L; Mullins CS; Schafmayer C; Zeißig S; Linnebacher M
Cancer Commun (Lond); 2021 Nov; 41(11):1137-1151. PubMed ID: 34563100
[TBL] [Abstract][Full Text] [Related]
30. Circulating MiR-1290 as a potential diagnostic and disease monitoring biomarker of human gastrointestinal tumors.
Xu L; Cai Y; Chen X; Zhu Y; Cai J
BMC Cancer; 2021 Sep; 21(1):989. PubMed ID: 34479528
[TBL] [Abstract][Full Text] [Related]
31. Immunomodulatory therapy in refractory/recurrent ovarian cancer.
Chen CY; Lai CH; Yang LY; Tang YH; Chou HH; Chang CJ; Lin CT
Taiwan J Obstet Gynecol; 2015 Apr; 54(2):143-9. PubMed ID: 25951718
[TBL] [Abstract][Full Text] [Related]
32. Astrocyte Elevated Gene-1 as a Novel Clinicopathological and Prognostic Biomarker for Gastrointestinal Cancers: A Meta-Analysis with 2999 Patients.
Luo Y; Zhang X; Tan Z; Wu P; Xiang X; Dang Y; Chen G
PLoS One; 2015; 10(12):e0145659. PubMed ID: 26710214
[TBL] [Abstract][Full Text] [Related]
33. Local Tumor Treatment in Combination with Systemic Ipilimumab Immunotherapy Prolongs Overall Survival in Patients with Advanced Malignant Melanoma.
Theurich S; Rothschild SI; Hoffmann M; Fabri M; Sommer A; Garcia-Marquez M; Thelen M; Schill C; Merki R; Schmid T; Koeberle D; Zippelius A; Baues C; Mauch C; Tigges C; Kreuter A; Borggrefe J; von Bergwelt-Baildon M; Schlaak M
Cancer Immunol Res; 2016 Sep; 4(9):744-54. PubMed ID: 27466265
[TBL] [Abstract][Full Text] [Related]
34. The impact of neural invasion severity in gastrointestinal malignancies: a clinicopathological study.
Liebl F; Demir IE; Mayer K; Schuster T; DʼHaese JG; Becker K; Langer R; Bergmann F; Wang K; Rosenberg R; Novotny AR; Feith M; Reim D; Friess H; Ceyhan GO
Ann Surg; 2014 Nov; 260(5):900-7; discussion 907-8. PubMed ID: 25379860
[TBL] [Abstract][Full Text] [Related]
35. Seropositivity for MIA and S100 in patients with gastrointestinal carcinomas.
Wagner V; Rudi J; Näher H; Stremmel W
Med Oncol; 2000 Feb; 17(1):35-8. PubMed ID: 10713658
[TBL] [Abstract][Full Text] [Related]
36. Neoadjuvant immunotherapy in primary and metastatic colorectal cancer.
Kanani A; Veen T; Søreide K
Br J Surg; 2021 Dec; 108(12):1417-1425. PubMed ID: 34694371
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor response in metastatic renal cell carcinoma.
Brown LC; Zhu J; Desai K; Kinsey E; Kao C; Lee YH; Pabla S; Labriola MK; Tran J; Dragnev KH; Tafe LJ; Dayyani F; Gupta RT; McCall S; George DJ; Glenn ST; Nesline MK; George S; Zibelman M; Morrison C; Ornstein MC; Zhang T
J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36252996
[TBL] [Abstract][Full Text] [Related]
38. Characterization of the T cell receptor repertoire and melanoma tumor microenvironment upon combined treatment with ipilimumab and hTERT vaccination.
Ellingsen EB; Bounova G; Kerzeli I; Anzar I; Simnica D; Aamdal E; Guren T; Clancy T; Mezheyeuski A; Inderberg EM; Mangsbo SM; Binder M; Hovig E; Gaudernack G
J Transl Med; 2022 Sep; 20(1):419. PubMed ID: 36089578
[TBL] [Abstract][Full Text] [Related]
39. Ipilimumab and Gemcitabine for Advanced Pancreatic Cancer: A Phase Ib Study.
Kamath SD; Kalyan A; Kircher S; Nimeiri H; Fought AJ; Benson A; Mulcahy M
Oncologist; 2020 May; 25(5):e808-e815. PubMed ID: 31740568
[TBL] [Abstract][Full Text] [Related]
40. Tumor response as defined by iRECIST in gastrointestinal malignancies treated with PD-1 and PD-L1 inhibitors and correlation with survival.
Xie P; Zheng H; Chen H; Wei K; Pan X; Xu Q; Wang Y; Tang C; Gevaert O; Meng X
BMC Cancer; 2021 Nov; 21(1):1246. PubMed ID: 34798858
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
